MWVC
UTHR icon

Morgens Waterfall Vintiadis & Co’s United Therapeutics UTHR Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,700
Closed -$1.95M – 45
2023
Q1 		$1.95M Buy
8,700
+2,300
+36% +$567K 1.6% 25
2022
Q4 		$1.78M Sell
6,400
-4,000
-38% -$1.01M 1.54% 29
2022
Q3 		$2.18M Buy
10,400
+7,200
+225% +$1.61M 2.39% 17
2022
Q2 		$754K Buy
+3,200
New +$651K 0.71% 27

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's UTHR Position: Q2 2023 in Review

Morgens Waterfall Vintiadis & Co sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 8,700 shares — an estimated $1.95M sold.

Morgens Waterfall Vintiadis & Co first reported a position in UTHR in Q2 2022 and held it in 4 quarters. The position peaked at $2.18M in Q3 2022. 475 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

  • Morgens Waterfall Vintiadis & Co reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 8,700 United Therapeutics shares in Q2 2023, an estimated $1.95M.
  • Morgens Waterfall Vintiadis & Co first reported a position in United Therapeutics in Q2 2022 and held it in 4 quarters.
  • Morgens Waterfall Vintiadis & Co's United Therapeutics position peaked at $2.18M in Q3 2022.
  • 475 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q2 2023, filed 14 Aug 2023.